Blue Horseshoe Stocks: ECYT Recap & More

Endocyte, Inc. ECYT

Our first order of business this morning is to review the recent performance of ECYT, which we initially slated for observation in our report on February 28th. At the time, the stock had been slowly gaining momentum for much of February, and it looked ripe for a more pronounced breakout.

That day, as the stock was trading for as little as 4.51, we witnessed an explosion in volume that has precipitated a very impressive run, persisting for over two weeks up to the present time. Yesterday’s session brought a new high of 11.54 in ECYT, which marks an upswing of 156% in a relatively short time frame.

Valeant Pharma International, Inc. VRX

On Monday morning, we came up with some options ideas for VRX, which we noted was “ready for a bottom bounce”. We also made reference to a huge Form-4 buy of $108.8M came in as well, which led us to postulate that “for now the stock has gone as low as it’s going to go.”

We couldn’t have been any more spot-on in our assessment of VRX, and the result has been a solid performance for the short-term calls we put on watch, the VRX Weekly $15 & $15.50 Calls. The $15′s ran from .65-1.15 for a gain of 77%, while the $15.50′s moved from a low of .30 to .71, an increase of 137%

We had some longer-term ideas as well which we will likely come back to in an upcoming report, as it appears VRX will continue to head up. On that note, we’ll also look to roll up our strike prices on the weekly calls to the $16 & $16.50′s.


Fresh Options Idea:

Walmart, Inc. WMT 04/20 $95-97.50 Calls

Extended Watchlist:

Incoming search terms:

  • Y3U9

Blue Horseshoe Stocks: NFLX Options & More

Sorrento Therapeutics, Inc. SRNE

Recently we’ve been delving back into our reports from late 2017, to review the ones that have made notable moves, and next up on the list SRNE.

We last signaled our interest in this as a bottom-watch play back on November 16th, and while it took a couple weeks for it to get out of its sideways-trading funk, the beginning of December brought the start of a fantastic run from an ultimate low of 2.15 that has persisted into the present. Yesterday the stock reached a new annual high of 8.05 (highest PPS since October ’16), marking an increase of 274%

This most recent push in what has definitely been a steady but sharp rise of the past six weeks may have been helped along by Celgene’s (CELG) buyout of Juno Therapeutics (JUNO), which share a market space with SRNE. The company also has some promising treatments in its pipeline.

Volume has recently been ramping up in a big way, too, so we’ll definitely continue to have an eye on this stock’s activity.

Netflix, Inc. NFLX – Options Idea

We’re always looking for a good opportunity to make some quick gains in the wake of a big company’s earnings, and NFLX is one that we’ve had quite a bit of experience with in that arena.

That’s why we’re going to enter an idea into the log this morning in the NFLX Weekly $247.50-255 Calls as the company posted a promising report including the addition of more than eight million new subscribers even despite its recent price increases.

Shares of NFLX broke a double top and are in blue skies, hitting a new all time high, so we’re very interested to track the ideas we’ve identified. They may be able to furnish us with some impressive gains.

Extended Watchlist:

Incoming search terms:

  • NZ5L

Blue Horseshoe Stocks: DIS, TRXC Recaps & More

 TransEnterix, Inc. TRXC

We made a good catch when we included TRXC in yesterday morning’s premarket report, after it was reported that the company’s robotic surgery device got the regulatory approval it needed.

The result was a very nice run from a low of  2.15 to 3.05, the highest PPS the stock has seen since the spring of 2016. That works out to an intraday push of 42% and this morning TRXC is edging even higher in before-hours trading, so we’ll want to continue to keep an eye on it moving forward.

Walt Disney Co. DIS

We highlighted some options ideas for Disney yesterday morning, after noticing that it had  a nice bottom setup on the chart, trading near its ten-month lows.

For a near-term idea we signaled the DIS Weekly $96-98 Calls and among those five contracts, three produced opportunities for solid single-session gains.

$97 Calls – Range: 1.15-1.57 – Max Gain: 37%
$97.50 Calls – Range: .81-1.22  – Max Gain: 51%.
$98 Calls – Range: .49-.89 – Max Gain: 82%

We also noticed that the $98.50s had the highest open interest, so we will want to roll up our observed range a little and keep an eye on those for the remainder of the week.

Netflix, Inc. NFLX

We also want to put a few options contracts in the NFLX chain on watch. The stock has been in a general uptrend for nearly all of 2017, with the exception of one month between late July and late August. Currently the stock is approaching extreme overbought levels on the strength index just as it was prior to that downturn.

On the flip side, boosted guidance and a strong earnings call this morning could make things interesting. Due to these opposing factors, we’re going to want to watch some contracts on both sides of the fence, depending on NFLX’s behavior once regular market hours kick in.

If the stock can’t get above $207.50, we’re going to zero in on the NFLX Weekly $207.50 and $205 Puts. Conversely, if it holds above $200 on any pullbacks, we’ll focus on the Weekly $200-205 Calls.

Extended Watchlist:

Blue Horseshoe Stocks: CAPR, VYGR, HMNY Recaps & More

Recent Big Winners

We have a large group of updates on previously called plays that we wanted to briefly swing back around and report performance information on this morning:

Voyager Therapeutics, Inc. VYGR – We alerted on VYGR on the 6th of September, witnessing a low of 12.33 and after finishing the rest of the month on a bullish streak, Friday brought a new high of 22.28. That’s a three week swing of 81%, which is fantastic for a stock in this price range.

Capricor Therapeutics, Inc. CAPR – We signaled our interest in CAPR later on in September,on the 20th. The following day we observed a low of 1.80, and like the above-mentioned play, it never looked back. Friday’s new high of 3.05, represented a 69% increase in just over a week’s time.

Helios and Matheson Analytics Inc. HMNY – We’ve discussed this one quite a bit recently, also beginning on September 20th. That morning  we saw a low of 5.469, and once again, it has been nothing but bullish moves ever since. On Friday the stock hit 14.17, marking a fantastic move of 159% in a little over a week.

Blackberry Ltd. BBRY – Options Recap

We also wanted to provide the final figures on the BBRY options we signaled in Thursday’s premarket report, the BBRY Weekly $9.50 & $10 Calls.  Friday’s session brought new highs for both sets.

The final intraweek range on the $9.50 Calls ended up being from .37 to 1.81 for a gain of 389%, while the $10′s breached the ten-bagger mark with an extraordinary run of 1025% from .12-1.35. Even readers who just caught Friday morning’s mention of these plays could still have made single-session profits of up to 103% and 202%, respectively.

Extended Watchlist:

Blue Horseshoe Stocks: IDXG Recap & More

Interpace Diagnostics Group, Inc. IDXG

We last talked about IDXG on the 16th of last month. (Please excuse us for being currently unable to provide the link to that report like we normally would, as our primary servers are located in Houston, and our service provider is still recovering in the wake of Hurricane Harvey.) Subsequent to that mention, we observed a low of .72 in IDXG, and the run we’ve seen has been pretty impressive.

Yesterday the stock hit 1.73, which represents a 140% increase, and the stock closed with strength just below its high of day, so we’ll be interested to see if there will be further gains in store. The key for IDXG will be to maintain above the NASDAQ minimum bid requirement of a dollar per share on any pullbacks.

Insmed, Inc. INSM – Options Update

We highlighted our interest in a set of options for INSM in yesterday’s report to try to take advantage of the flux in activity caused by the company’s positive Phase III results on its rare lung disease treatment study.

We saw the beginnings of what could be a good idea that we’ll want to continue tracking in the INSM 09/15 $27-30 Calls. The $27′s we’re the only ones that were pushed into the money, and they did manage an intraday run from a low of .95 to 1.60 for a 68% swing on the day. We’ll continue to keep an eye on these contracts if INSM can manage to record higher lows over the next few sessions.

Extended Watchlist: